Status:

ENROLLING_BY_INVITATION

The Influence of Treatment Format on Schema Therapy for Borderline Personality Disorder

Lead Sponsor:

University of Amsterdam

Collaborating Sponsors:

Academic Center for Trauma and Personality

Arkin Mental Health Care

Conditions:

Borderline Personality Disorder

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to compare etc. in patients with borderline personality disorder pure individual schema therapy to combined individual-group schema therapy. The main questions it ai...

Detailed Description

Schema Therapy (ST) for Borderline Personality Disorder (BPD) was originally developed and tested as an individual treatment. Since 2009 group-ST became popular as an supposedly efficient alternative....

Eligibility Criteria

Inclusion

  • BPD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), assessed with the Structured Clinical Interview for the DSM-5 Personality Disorders (SCID-5-PD), as primary diagnosis
  • BPDSI total score ≥ 20 (i.e, severity in the BPD range, Giesen-Bloo et al., 2010)
  • Ability to understand, read, write and speak Dutch, or English if the site has research assistants and therapists of both conditions that are sufficiently fluent in English, as well as an English ST group (as at ACTP).

Exclusion

  • DSM-5 substance use disorder that needs clinical detox according to the clinical staff (after 6 weeks of abstinence participation is possible).
  • Comorbid psychotic disorder (patients with temporary psychotic problems falling under BPD criterion 9 are not excluded)
  • DSM-5 Bipolar disorder, type 1 (current or past)
  • Acute suicide risk
  • Intelligence Quotient (IQ) \< 80
  • Serious neurological problems such as dementia
  • Patients should not start with any form of psychological treatment during screening or during the study's waitlist or treatment. (Low frequency supportive treatment may be continued during wait and screening, but not during the study treatment.)
  • Not able or willing to plan participation in the treatment sessions. Note 1. In case of suspicion of exclusion criteria that need specific assessment, like IQ and dementia, a formal diagnostic assessment needs to be done before in/exclusion can be decided.
  • Note 2. No other psychological treatment during the study follow-up period is provided, unless this is necessary (clinical judgment). The 1 year treatment-free follow-up period is part of the treatment protocol, to help patients gain experience with life without mental health care. After 1 year further treatment can be offered, if indicated.

Key Trial Info

Start Date :

November 10 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2027

Estimated Enrollment :

132 Patients enrolled

Trial Details

Trial ID

NCT05986552

Start Date

November 10 2023

End Date

December 30 2027

Last Update

January 20 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Academic Center for Trauma and Personality ACTP

Amsterdam, Netherlands, 1001NK

2

Arkin Mental Health Care

Amsterdam, Netherlands, 1093 MB